BMO Capital analyst Evan Seigerman assigned a Hold rating to Gilead Sciences (GILD – Research Report) yesterday and set a price target of $90.00. The company’s shares closed yesterday at $81.39.
According to TipRanks, Seigerman is a 4-star analyst with an average return of 6.9% and a 52.90% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Mirati Therapeutics.
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $91.56, implying a 12.50% upside from current levels. In a report released today, Morgan Stanley also maintained a Hold rating on the stock with a $81.00 price target.
See today’s best-performing stocks on TipRanks >>
GILD market cap is currently $105.4B and has a P/E ratio of 30.78.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year. Most recently, in November 2022, Diane Wilfong, the SVP, Controller & CAO of GILD sold 6,416.00 shares for a total of $535,736.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
Read More on GILD: